Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human tissue-type plasminogen activator derivative
- Development stage
- Unknown
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Recombinant human tissue-type plasminogen activator derivative (rPA) is a thrombolytic agent designed to break down blood clots. It is a modified version of recombinant tissue-type plasminogen activator (rt-PA), which itself is a biosynthetic form of human tissue-type plasminogen activator (t-PA). Its mechanism of action involves converting plasminogen to plasmin, an enzyme that subsequently degrades fibrin, the main structural component of blood clots. This leads to the dissolution of the clot and restoration of blood flow. rPA is currently being investigated for the treatment of acute pulmonary embolism.
- Brand names
- RuitongliRetavaseRapilysin
- Other names
- recombinant human tissue-type plasminogen activator derivativereteplase recombinant
02
Targets
PAI-1 (Plasminogen activator inhibitor type 1)Fibrin (Factor Ia)PLAU (uPA)PLG (Plasminogen)
Beyond the preview
Go deeper on recombinant human tissue-type plasminogen activator derivative.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human tissue-type plasminogen activator derivative.